Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Appointed director
GALECTIN THERAPEUTICS INC (GALT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 ARS Form ARS - Annual Report to Security Holders:
10/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/14/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Georgia, August 14, 2023 –"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Georgia, May 15, 2023 –"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/25/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/14/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/30/2023 8-K Quarterly results
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Ga., March 2, 2023"
01/31/2023 5 10X Fund, L.P. (10% Owner) has filed a Form 5 on GALECTIN THERAPEUTICS INC
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
12/06/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/17/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/17/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer NORCROSS, Ga., October 12, 2022"
10/06/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/06/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/26/2022 8-K Amended existing or entered into new employment agreement with an officer
Docs: "Form of Warrant",
"Line of Credit Letter Agreement, by and between Richard E. Uihlein and the Company",
"Form of Convertible Promissory Note",
"Employment Amendment",
"2023 Deferred Stock Unit Agreement",
"2020 Deferred Stock Unit Amendment",
"NORCROSS, Ga., July 26, 2022"
05/16/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE,"
03/31/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Ga., March 31, 2022"
03/31/2022 10-K Annual Report for the period ended December 31, 2021
12/21/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Unsecured Convertible Promissory Note",
"Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein"
12/07/2021 8-K Quarterly results
12/03/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy